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Abstract
Background: This study investigated the correlation between renal microcirculation and coronary 
microcirculation in hypertensive patients.
Methods: Participants consisted of 231 consecutive candidates who were referred to the Second  
Affiliated Hospital of Wenzhou Medical University from March 2014 to May 2016 for elective coronary 
angiography due to suspected myocardial ischemia. All participants were evaluated for the index of 
microvascular resistance (IMR), coronary flow reserve (CFR), and fractional flow reserve (FFR) us-
ing a pressure wire. Blood and urine samples were collected for determination of the levels of urinary 
microalbuminuria (mALB), b2-microglobulin (b2-MG), serum cystatin C (CysC), and uric acid (UA). 
All participants were categorized into two groups according to the renal microcirculatory function. 
Results: Participants in the observation group had a higher IMR (31 ± 5 vs. 22 ± 6; p < 0.01) and 
a lower FFR (0.84 ± 0.10 vs. 0.87 ± 0.09 U; p < 0.05) during hyperemia than those in the control 
group. Linear regression tests revealed that mALB, b2-MG, CysC, and UA levels were positively cor-
related with IMR (r = 0.610, 0.553, 0.701, and 0.647, respectively, p < 0.01). The hs-CRP levels were 
positively correlated with IMR (r = 0.419, p < 0.01). Multiple regression analysis indicated that renal 
microcirculation was an independent predictor of IMR.
Conclusions: Renal microcirculatory dysfunction in hypertensive patients is characterized by higher 
IMR and lower FFR; in addition, it is closely correlated with an increased coronary microcirculatory 
resistance. (Cardiol J 2017; 24, 6: 623–632)
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Introduction
Renal and coronary microcirculation are im-
portant components of the circulatory system. Due 
to the special structure of the kidney, renal micro-
circulation is most susceptible to microvascular 
damage and is usually the site where the earliest 
microvascular injury occurs [1]. Hypertensive 
nephropathy, a type of hypertension-linked renal 
damage, is a common complication of hypertension. 
Long-term arterial hypertension initiates endothe-
lial damage and microvascular injury, subsequently 
causing a series of pathological changes in the 
kidney such as glomerular alterations [2, 3]. In the 
clinic, due to changes in the function of the glo-
meruli, the levels of several biochemical indexes, 
including the levels of urinary microalbuminuria 
(mALB), b2-microglobulin (b2-MG), serum cys-
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tatin C (CysC), and uric acid (UA), are increased. 
Hence, these indexes reflect the functional status 
of renal microcirculation and are important indica-
tors of early renal damage [4]. 
Currently, three major indexes are used in 
clinical practice to evaluate coronary microcircula-
tory function. Both coronary flow reserve (CFR) 
and fractional flow reserve (FFR) are important 
indicators of coronary microcirculatory function, 
while the index of microvascular resistance (IMR) 
is used to evaluate coronary microvascular function 
[5, 6]. Among these three indexes, both the FFR 
and IMR can be simultaneously measured with 
a guide wire carrying temperature and pressure 
sensors; in addition, they reflect coronary physiolo-
gy more stably and more accurately when compared 
with CFR [7]. For instance, IMR has been shown 
to be independent of the severity of epicardial 
coronary stenosis [8–10], and its increase indicates 
microcirculatory dysregulation [11]. Also, IMR 
has diagnostic and prognostic values for a variety 
of cardiovascular events [12–17]. Moreover, some 
cardiovascular risk factors such as diabetes and 
smoking can affect IMR [18, 19]. Similarly, FFR has 
become an important assessor for coronary artery 
function and is superior to CFR, as demonstrated 
in a number of clinical trials [20, 21]. Hence, simul-
taneous determination of FFR and IMR has been 
recommended to evaluate coronary physiology and 
pathophysiology comprehensively [5]. 
Recent studies have shown that patients 
with a slight decrease in renal function exhibit an 
increased cardiovascular event rate [22–24], but 
exact underlying mechanisms are not completely 
known. A link between a decline in creatinine 
clearance and an impaired CFR has been shown 
[25]; however, the relationship between the FFR 
and IMR has not been reported. This study aimed 
to investigate the relationship between renal mi-
crocirculatory dysfunction and an increased coro-
nary vascular resistance in hypertensive patients. 
The outcomes of the present study are expected 
to provide evidence for renal microcirculatory 
dysfunction to be used as an indicator for evalua-
tion and prediction of increased coronary vascular 
resistance in hypertensive patients. 
Methods
Participant selection
A total of 231 consecutive hypertensive pa-
tients who visited the Second Affiliated Hospital of 
Wenzhou Medical College for coronary angiography 
between March 2014 and May 2016 were selected 
for this study. Indications for coronary angiography 
included unexplained chest pain, chest symptoms, 
and potential myocardial ischemia as revealed by 
a variety of noninvasive examinations (e.g., treadmill 
and stress echocardiography). Patients having one 
or more of the following were excluded from this 
study: diabetes, asthma, acute and chronic myo-
cardial infarction, collateral circulation revealed 
by coronary angiography, uncontrolled heart fail-
ure, severe bradycardia, stroke, connective tis-
sue disease, autoimmune disease, cancer, acute 
and chronic infection, and a variety of acute and 
chronic kidney diseases except for hypertension-
linked nephropathy. After application of inclusion 
and exclusion criteria, 96 patients with a degree 
of 50–70% stenosis as revealed by coronary an-
giography were included in this study, and all 
96 patients underwent coronary pressure guide wire 
measurements. Based on renal microcirculatory 
function status, these patients were divided into 
two groups: an observation group and a control 
group. The observation group consisted of 52 pa-
tients with abnormal renal microcirculation, which 
included 30 males and 22 females, with a mean age 
of 56 ± 12 years old. The control group contained 
44 patients with normal renal microcirculation, 
including 28 males and 16 females, with a mean 
age of 56 ± 11 years. All participants signed an 
informed consent form. This study was approved 
by the Ethics Committee at the Second Affiliated 
Hospital of Wenzhou Medical College. The general 
information of the participants in these two groups 
are shown in Table 1.
Measurement of biochemical parameters
The patients fasted overnight and blood was 
collected the following early morning. An ADYIA 
2400 automatic biochemical analyzer was used 
to determine serum UA and CysC levels with 
UA enzyme method and latex-enhanced immu-
noturbidimetric assay, respectively. The middle 
portion of the first urine collected from patients 
in the morning under unstressed conditions was 
used to determine the b2-MG (IMMULITE2000 
chemiluminescence immunoassay analyzer, USA) 
and mALB (IMMAGE800 immune turbidity ana-
lyzer) levels. No preservatives were added to the 
collected urine. The criteria used to determine 
renal microcirculatory dysfunction were as follows: 
(1) mALB ≥ 30 mg/L (range: 0–19 mg/L); (2) serum 
UA, male ≥ 380 μmol/L (range: 149–416 μmol/L), 
female ≥ 360 μmol/L (range: 89–357 μmol/L); 
(3) CysC ≥ 1.4 mg/L (range: 0.51–1.09 mg/L); (4) uri-
nary b2-MG ≥ 0.3 mg/L (range: 0.013–0.293 mg/L). 
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Among these indexes, mALB was the primary in-
dicator; while serum UA, serum CysC, and urinary 
b2-MG were secondary indicators. The patient was 
diagnosed with renal microcirculatory dysfunction 
when he/she had the primary indicator and one of 
the three secondary indicators.
Coronary angiography
Digital subtracted angiography was performed 
with a cardiovascular imaging system (Innova-2100, 
GE, USA). 6 F Judkins catheters were used for all 
patients and passed through the radial artery for 
left or right coronary angiography, whichever was 
selected. Preoperatively, all patients were orally 
administered with the same doses of clopidogrel, 
aspirin, and atorvastatin calcium. After sheath 
puncture, 200 μg of nitroglycerin and 5,000 IU of 
heparin were routinely injected.
Measurement of coronary artery pressure 
A pressure guide wire (St. Jude Medical, Inc., 
USA) was used to measure the coronary artery 
Table 1. Comparison of demographic and basic biochemical data between the control and observation 
groups.
Characteristic Observation group (n = 52) Control group (n = 44) P
Age [years] 56 ± 12 56 ± 11 0.897
Gender, male 30 (58%) 28 (64%) 0.553
BMI [kg/m2] 28.69 ± 5.34 27.42 ± 4.30 0.206
Smoker 23 (44%) 19 (43%) 0.948
Diabetes mellitus 18 (36%) 17 (39%) 0.683
Dyslipidemia 19 (37%) 19 (43%) 0.507
Previous PCI 6 (12%) 5 (11%) 0.979
FBG [mmol/L] 6.01 ± 1.17 5.92 ± 0.95 0.667
Creatinine [μmoI/L] 78 72 0.054
TC [mmol/L] 5.28 ± 0.64 5.28 ± 0.79 0.992
TG [mmol/L] 1.70 ± 0.53 1.65 ± 0.60 0.628
LDL-C [mmol/L] 3.11 ± 0.53 3.09 ± 0.62 0.828
HDL-C [mmol/L] 1.38 ± 0.33 1.46 ± 0.49 0.321
SBP [mm Hg]* 139 ± 12 138 ± 13 0.676
DBP [mm Hg]* 78 ± 11 75 ± 10 0.207
mALB [mg/L] 120.7 ± 29.3 50.6 ± 22.9 0
UA [μmol/L] 380 ± 111 318 ± 111 0.008
CysC [mg/L] 1.67 ± 0.75 1.19 ± 0.51 0.001
b2-MG [μg/L] 294 ± 58 184 ± 68 0
Hs-CRP 3.7 ± 1.5 2.5 ± 0.9 0
Medications:
Metoprolol (50 mg/d) 39 (75%) 32 (73%) 0.800
Amlodipine (5 mg/d) 29 (56%) 21 (48%) 0.432
Aspilin 52 (100%) 44 (100%) 1.000
Clopidogrel 52 (100%) 44 (100%) 1.000
Atorvasatin 52 (100%) 44 (100%) 1.000
Nitrates 30 (58%) 29 (66%) 0.410
Losartan (50 mg/d) 31 (60%) 28 (64%) 0.687
LVEF [%] 55 ± 7 56 ± 8 0.516
Values are expressed as mean ± standard deviation for quantitative variables and n (%) for qualitative variables; *Data from ambulatory blood 
pressure; BMI — body mass index; CysC — serum cystatin C; DBP — diastolic blood pressure; FBG — fasting blood glucose; HDL-C — high-
-density lipoprotein cholesterol; hs-CRP — high-sensitivity C-reactive protein; LDL-C — low-density lipoprotein cholesterol; LVEF — left  
ventricular ejection fraction; mALB — microalbuminuria; PCI — percutaneous coronary intervention; SBP — systolic blood pressure; TC — 
total-cholesterol; TG — triglycerides; UA — uric acid; b2-MG — b2-microglobulin
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pressure for all patients. Coronary angiography 
showed critical coronary artery stenosis. Briefly, 
(1) the pressure sensor was opened to air, its pres-
sure was set to zero, and zero calibration was made 
for the pressure guide wire in vitro; (2) The 6 F 
guiding catheter was delivered to the coronary os-
tia, and the pressure guide wire passed through the 
catheter port, followed by calibration of pressure 
and temperature so that the tip of the guide wire 
and guiding catheter had an equivalent pressure, 
which was comparable to the mean aortic pressure 
(Pa), as a reference pressure. The temperature 
after correction served as a reference for the 
change of subsequent temperatures; (3) The guide 
wire passed through the lesion and reached more 
than two-thirds of the total length of the vessel; 
(4) nitroglycerin (200 μg) was administered into 
the coronary artery; (5) 3 mL of 0.9% sodium chlo-
ride (room temperature) was rapidly injected. The 
pressure guide wire recorded the first temperature 
curve when sodium chloride passed through the 
coronary ostia, and the second temperature curve 
was recorded when sodium chloride flowed to the 
distal end sensor of the guide wire. The time dif-
ference between these two temperature curves 
was defined as the average conduction time (Tmn). 
A baseline mean transit time (bTmn) was obtained 
from three continuous operations; (6) Adenosine 
(140 μg/kg/min, 3–6 min) was infused through the 
elbow vein to generate the maximum coronary 
hyperemia, and then step 5 was repeated to obtain 
hyperemic mean transit time (hTmn); (7) At the 
conclusion of the procedure, the screen simulta-
neously displayed Pa at resting and hyperemia as 
well as the distal coronary artery pressure (Pd).
Calculation of the index  
of microvascular resistance
The IMR was calculated as described previous-
ly [20]: (1) The simplified formula IMR = PdTmn 
was used for mild-to-moderate coronary stenosis 
with a FFR > 0.80; (2) IMR = PaTmn [(Pd – Pw) 
/ (Pa – Pw)] was used for severe coronary stenosis 
with FFR < 0.80, in which Pw indicates coronary 
artery wedge pressure, i.e. average pressure of 
the distal lesion when the coronary artery is com-
pletely narrowed or balloon-incarcerated.
Statistical analysis
All statistical analyses were performed with 
SPSS 20.0 software (USA). Measurement data un-
derwent the normality test for normal distribution 
examination. Continuous variables were expressed 
as the mean ± standard deviation (SD), and the in-
dependent t test was used for data comparison be-
tween two groups. Numerical data were expressed 
as n (%), and significance was determined with 
the c2 test. Linear correlation analysis was used 
to evaluate the relationship between indicators of 
renal microcirculation and IMR. Multiple linear re-
gression models were used to evaluate associations 
between exposure and outcome variables. Both 
non-adjusted and multivariate-adjusted models 
were used. It was defined that exposure variables 
were mALB, b2-MG, serum UA, and CysC and that 
the outcome parameter was IMR. Other variables 
with a p value < 0.1 in univariate analyses were 
included in stepwise multiple regression models. 
P < 0.05 was considered statistically significant.
Results
Comparison of demographic and basic  
biochemical data between the control  
and observation groups
First, demographic and basic biochemical data 
of participants between the control and observation 
groups were compared. There were no significant 
differences with regard to age, sex, blood pressure, 
blood lipids, or blood glucose between these two 
groups (p > 0.05). However, the levels of urinary 
mALB and b2-MG as well as serum UA, CysC, and 
high-sensitivity C-reactive protein (hs-CRP) were 
significantly higher in the observation group than 
in the control group (p < 0.01) (Table 1). These 
data suggest that patients in the observation group 
had renal microcirculatory dysfunction.
Comparison of coronary angiography  
data between the control and  
observation groups
Next, clinical data obtained from coronary 
angiography between the control and observation 
groups were compared. As shown in Table 2, no 
significant differences in the cumulative number of 
diseased coronary arteries, morphological charac-
teristics, distribution of lesions, or Thrombolysis 
in Myocardial Infarction (TIMI) flow grade were 
observed between these two groups (p > 0.05). 
Comparison of coronary physiological  
indicators after adenosine injection  
between the control and observation groups
Next, hyperemia was induced in patients 
with an adenosine injection and clinical data were 
compared between control and observation groups. 
Under hyperemic conditions, the control and ob-
servation groups showed comparable Pa values 
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(p > 0.05). The observation group had significantly 
lower FFR (p < 0.05) and higher IMR (p < 0.01) 
compared to the control group, but no significant 
difference in CFR was noted between these two 
groups (p > 0.05) (Table 3). 
Determination of the correlation of urinary 
mALB and b2-MG as well as serum UA  
and CysC with the index of microvascular 
resistance
Next, linear regression analysis was used 
to explore the correlation of urinary mALB and 
b2-MG as well as serum UA and CysC with the 
IMR within each group. As shown in scatter plots in 
Figure 1, each of these four indexes, mALB, b2-MG, 
serum UA, and CysC, had a positive correlation 
with the IMR in each individual group.
Correlation analysis between hs-CRP levels 
and index of microvascular resistance
Linear regression analyses showed that 
hs-CRP levels were positively correlated with IMR 
(r = 0.419, p < 0.01, Fig. 2). 
Determination of univariate and  
multivariate factors related to an increased 
index of microvascular resistance 
Multivariate regression analysis was used 
to identify the factors that were correlated to an 
increased IMR in hypertensive patients. As shown 
Table 2. Comparison of procedural characteristics between the control and observation groups.
Observation group  
(n = 52)
Control group  
(n = 44)
P
Culprit vessel number 1 21 (40%) 21 (48%) 0.470
2 19 (37%) 14 (32%) 0.628
3 12 (23%) 9 (20%) 0.757
Lesion location of FFR and IMR LAD 30 (58%) 23 (52%) 0.595
LCX 14 (27%) 12 (27%) 0.969
RCA 8 (15%) 9 (20%) 0.517
TIMI flow grade 0 0 0 1
1 0 0 1
2 4 (8%) 2 (5%) 0.526
3 48 (92%) 42 (95%) 0.526
Total number of lesions 71 62
Lesion characteristics A+B1 30 (42%) 29 (47%) 0.601
B2+C 41 (58%) 33 (53%) 0.601
Lesion distribution LMCA 5 (7%) 4 (6%) 0.892
LAD 34 (48%) 28 (45%) 0.753
Circumflex 18 (25%) 15 (24%) 0.877
SYNTAX Score 29 24 0.635
FFR — fractional flow reserve; IMR — index of microvascular resistance; LAD — left anterior descending artery; LMCA — left main coronary 
artery; LCX — left circumflex artery; RCA — right coronary artery; TIMI — Thrombolysis in Myocardial Infarction
Table 3. Comparison of coronary physiological indicators after adenosine injection between control 
and observation groups.
Characteristic Observation group (n = 52) Control group (n = 44) P
Arterial pressure [mm Hg] 84 ± 8 85 ± 8 0.370
Fractional flow reserve 0.84 ± 0.10 0.87 ± 0.09 0.045
Coronary flow reserve 1.83 ± 0.38 1.99 ± 0.54 0.086
Index of microvascular resistance 31 ± 5 22 ± 6 0.000
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in Table 4, the levels of urinary mALB and b2-MG 
as well as serum UA and CysC were determined as 
independent predictors for IMR elevation.
Discussion
The major finding from this study was a strong 
correlation between renal microcirculatory dys-
function and increased coronary microcirculatory 
resistance in hypertensive patients. Therefore, 
hypertensive patients with poorer renal function 
were more prone to develop higher coronary mi-
crocirculatory resistance than those with normal 
renal function. 
The microcirculatory system is composed of 
arterioles, capillaries, and venules. The renal mi-
crocirculation is a balloon-shaped mesh structure 
that is not in direct contact with the veins and forms 
the glomerular capillary and peritubular vascular 
network. In the early stage of hypertensive ne-
phropathy, two major pathological events occur: 
1) increased permeability of the glomerular filtration 
membrane and/or impaired protein recovery of 
renal tubules resulting in elevated levels of urinary 
mALB and b2-MG as well as serum CysC and UA, 
and 2) small arteries have low blood flow and low 
velocity during both systole and diastole [26, 27]. 
CysC is released by glomerular filtration and then 
Figure 1. Correlation between renal microcirculatory dysfunction and increased coronary microcirculatory resistance 
in hypertensive patients; A. Correlation between microalbuminuria (mALB) and the index of microvascular resistance 
(IMR); B Correlation between b2 microglobulin (b2-MG) and the IMR; C. Correlation between uric acid (UA) and the 
IMR; D. Correlation between serum cystatin C (CysC) and the IMR. 
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is reabsorbed through the proximal tubules. Hence, 
the circulating levels of CysC reflect changes in the 
glomerular filtration rate. In addition, renal tubules 
are sensitive to ischemia, which results from 
a hypertension-linked decrease in renal perfusion, 
and renal tubular injury causes high levels of serum 
UA [28]. Therefore, levels of urinary mALB and 
b2-MG as well as serum UA and CysC reflect renal 
microcirculatory function, among which mALB is 
the major indicator of early kidney damage and vas-
cular lesions resulting from hypertension [29]. In 
the present study, these four biochemical indexes 
to evaluate the renal microcirculatory function in 
hypertensive patients were used. 
Previous studies have shown a strong correla-
tion between chronic kidney disease and cardiovas-
cular events/increased all-cause mortality, and this 
correlation is not affected by traditional risk factors 
[30]. For instance, patients with chronic kidney 
disease associated with an elevated CFR had an 
increased incidence of long-term cardiovascular 
Figure 2. Correlation analysis between high-sensitivity 
C-reactive protein (hs-CRP) levels and index of micro-
vascular resistance (IMR) in hypertensive patients.
Table 4. Determination of factors related to an increased index of microvascular resistance.
Univariate  
OR
Logistic 95%  
CI
Regression  
P
Multivariate  
OR
Logistic  
95% CI
Regression  
P
Age –0.1 –0.2–0.0 0.062
BMI 0.2 –0.1–0.5 0.182
Smoking 7.0 4.6–9.3 < 0.001 1.63 –0.1–3.4 0.078
Diabetes mellitus 6.9 4.4–9.3 < 0.001
Male gender 4.7 2.1–7.3 0.001
Dyslipidemia –1.7 –4.4–1.1 0.238
Previous PCI 2.6 –1.6–6.9 0.228
LVEDD 0.1 –0.2–0.3 0.621
Ejection fraction 0.0 –0.2–0.1 0.702
ACEI/ARB –0.6 –3.4–2.2 0.681
Beta-blocker –2.0 –5.1–1.0 0.198
Nitrates 0.2 –2.6–3.0 0.863
CCB 0.4 –2.3–3.2 0.758
Creatinine 0.1 0.0–0.2 0.228
mALB 0.1 0.1–0.1 < 0.001 0.04 0.02–0.06 < 0.001
UA 0 0.0–0.0 < 0.001 0.01 0.006–0.022 < 0.001
CysC 6.9 5.5–8.3 < 0.001 3.30 2.00–4.60 < 0.001
b2-MG 0 0.0–0.1 < 0.001 0.02 0.01–0.03 < 0.001
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; BMI — body mass index; BMI — body mass index; 
CCB — calcium channel blockers; CI — confidence interval; CysC — serum cystatin C; LVEDD — left ventricular end-diastolic dimension; 
mALB — microalbuminuria; OR — odds ratio; PCI — percutaneous coronary intervention; PCI — percutaneous coronary intervention;  
UA — uric acid; b2-MG — b2-microglobulin
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events [31, 32]. End-stage renal disease has also 
been shown to be tightly linked to the coronary 
slow-flow phenomenon [31], which often suggests 
the presence of increased coronary microcircula-
tory resistance [33]. A more recent study has re-
vealed that a variety of heart and kidney diseases 
can influence each other through neuroendocrine 
feedback mechanisms at an early stage [34]. For 
example, mALB-positive hypertensive patients 
often have more severe coronary artery stenosis 
than mALB-negative patients, and this prediction is 
independent of other risk factors, including diabe-
tes, hyperlipidemia, smoking, obesity, and age [35]. 
On the other hand, serum CysC has been shown 
to be a risk predictor of adverse cardiovascular 
outcomes in patients with cardiovascular diseases 
[36, 37], and it has been proposed to have a clinical 
value in stratification of acute coronary syndrome 
[38, 39]. In the present study, it was found that oc-
currence rate of coronary lesions in the observation 
group was slightly higher than that in the control 
group, but no statistical significance was observed. 
The potential cause for this insignificance may have 
been due to the small sample size used in the pre-
sent study. However, lower FFR but a higher IMR 
in the observation group than in the control group 
was found, suggesting the correlation of renal micro-
circulatory dysfunction and an increased coronary 
microcirculatory resistance. Further, it was found 
that each of these early indicators of renal dysfunc-
tion was an independent risk factor for increased 
IMR. Therefore, in the presence of hypertension, 
it was believed that the progression of kidney and 
coronary diseases share common mechanisms. In 
addition, a previous study has shown that renal 
microcirculatory lesions usually occur earlier in 
hypertensive patients than coronary lesions [1], 
implying that a variety of indicators for kidney 
microcirculation may also provide an early warning 
to some degree for the development of coronary 
lesions. However, this premise needs to be further 
corroborated in a large-scale multi-centered study 
in future. Consistent with previous findings [40, 41], 
it was also revealed that early renal dysfunction is 
an independent predictor of coronary heart disease, 
but the underlying mechanisms are not completely 
understood and merit further investigation. 
It has been well documented that endothelial 
dysfunction and inflammation play important roles 
in the development of chronic hypertensive kidney 
disease and adverse cardiovascular events [42, 43] 
and that microalbuminuria often indicates nonspe-
cific injuries to blood vessels [44]. For instance, 
Tsioufis et al. [45] have reported that mALB-positive 
hypertensive patients had higher CRP levels than 
mALB-negative patients. Since CRP is the strong-
est inflammatory marker of atherosclerosis and is 
a strong predictor of vascular events [46], the above 
finding argued that the mALB-positive hypertensive 
patients were under systemic stress. Consistent with 
the above observation, in the present study, we found 
that the hs-CRP level in the observation group was 
significantly higher than that in the control group, 
suggesting that inflammation may be an important 
mechanism underlying renal microcirculatory dys-
function and increased resistance of coronary mi-
crocirculation. Mechanistically, CRP has been shown 
to stimulate monocytes to release proinflammatory 
cytokines, such as interleukin-6 and tumor necrosis 
factor-b, and to mediate the generation of intercel-
lular adhesion molecule and vascular cell adhesion 
molecule, resulting in increased anti-inflammatory 
responses and endothelial dysfunction [47]. Also, the 
generation of UA is accompanied by the production 
of oxygen free radicals and hydrogen peroxide, which 
contribute to increased inflammation and NO inactiva-
tion, thus damaging endothelial cells and causing the 
coronary slow-flow phenomenon [48, 49]. In addition, 
high levels of UA may promote low-density lipopro-
tein cholesterol oxidation and lipid peroxidation, thus 
amplifying oxidative stress, promoting atherosclerotic 
plaque formation, increasing vascular resistance, and 
eventually slowing blood flow [49, 50].
Limitations of the study
Some limitations of this study need to be ac-
knowledged. For example, the present study had 
a small sample size and was a single center study. Also, 
patients with normal coronary or mild or severe coro-
nary stenosis were excluded from this study, which 
potentially brought in sample selection bias. In addi-
tion, drug use prior to coronary angiography might 
also have potentially affected IMR measurement.
Conclusions
In conclusion, it was demonstrated in the 
present study that impaired renal microcirculation 
is closely associated with an increased coronary 
microcirculatory resistance and that renal microcir-
culation is an independent risk factor for coronary 
microcirculation in hypertensive patients. Our 
findings also suggest that it is highly likely that 
hypertension-linked renal microcirculatory impair-
ment and an increase in coronary microcirculatory 
resistance share a common pathological basis.
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